Macquarie Group’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-249,495
| Closed | -$1.9M | – | 1669 |
|
|
2024
Q3 | $1.9M | Buy |
+249,495
| New | +$1.9M | ﹤0.01% | 1245 |
|
|
2022
Q4 | – | Sell |
-5,019
| Closed | -$80K | – | 1810 |
|
|
2022
Q3 | $80K | Sell |
5,019
-1,302
| -21% | -$20.8K | ﹤0.01% | 1818 |
|
|
2022
Q2 | $67K | Hold |
6,321
| – | – | ﹤0.01% | 1976 |
|
|
2022
Q1 | $103 | Sell |
6,321
-1,984
| -24% | -$32 | ﹤0.01% | 1937 |
|
|
2021
Q4 | $115K | Buy |
8,305
+1,803
| +28% | +$25K | ﹤0.01% | 1891 |
|
|
2021
Q3 | $93K | Sell |
6,502
-2,103
| -24% | -$30.1K | ﹤0.01% | 2003 |
|
|
2021
Q2 | $136K | Buy |
8,605
+253
| +3% | +$4K | ﹤0.01% | 1880 |
|
|
2021
Q1 | $85K | Sell |
8,352
-1,580
| -16% | -$16.1K | ﹤0.01% | 1955 |
|
|
2020
Q4 | $74K | Hold |
9,932
| – | – | ﹤0.01% | 1941 |
|
|
2020
Q3 | $34K | Buy |
9,932
+3,200
| +48% | +$11K | ﹤0.01% | 2032 |
|
|
2020
Q2 | $32K | Buy |
+6,732
| New | +$32K | ﹤0.01% | 2032 |
|
|
2018
Q1 | – | Sell |
-1,800
| Closed | -$9K | – | 2187 |
|
|
2017
Q4 | $9K | Buy |
+1,800
| New | +$9K | ﹤0.01% | 2271 |
|
|
2016
Q2 | – | Sell |
-25,529
| Closed | -$72K | – | 1569 |
|
|
2016
Q1 | $72K | Sell |
25,529
-113,719
| -82% | -$321K | ﹤0.01% | 1457 |
|
|
2015
Q4 | $1.44M | Buy |
139,248
+1,806
| +1% | +$18.6K | ﹤0.01% | 1009 |
|
|
2015
Q3 | $1.57M | Buy |
137,442
+23,807
| +21% | +$271K | ﹤0.01% | 1032 |
|
|
2015
Q2 | $1.7M | Buy |
113,635
+3,243
| +3% | +$48.4K | ﹤0.01% | 1066 |
|
|
2015
Q1 | $997K | Sell |
110,392
-31,775
| -22% | -$287K | ﹤0.01% | 1155 |
|
|
2014
Q4 | $1.73M | Buy |
142,167
+43,616
| +44% | +$530K | ﹤0.01% | 1058 |
|
|
2014
Q3 | $964K | Buy |
98,551
+64,451
| +189% | +$630K | ﹤0.01% | 1158 |
|
|
2014
Q2 | $435K | Buy |
+34,100
| New | +$435K | ﹤0.01% | 1334 |
|